Proton therapy and the European Particle Therapy Network: The past, present and future.

Cancer EPTN European research infrastructure European research networks Infrastructures de recherche européennes Proton therapy Protonthérapie Réseaux de recherche clinique européens

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 15 05 2020
revised: 19 05 2020
accepted: 20 05 2020
pubmed: 6 8 2020
medline: 9 10 2020
entrez: 6 8 2020
Statut: ppublish

Résumé

Proton therapy is delivered to selected cancer patients presenting with rare tumours, for which a dose escalation paradigm and/or a reduced dose-bath to the organs at risk is pursued. It is a costly treatment with an additional cost factor of 2-3 when compared to photon radiotherapy. Notwithstanding the 180'000 patients treated with protons, scars robust clinical evidence is available to justify the administration of this treatment modality. The European Particle Therapy Network (EPTN) was created in 2015 to answer the critical European needs for cooperation among protons and carbon ions centres in the framework of clinical research networks. EPTN with other European groups will launch a number of prospective clinical trials that could be practice changing if positive. Alternative way to generate clinical data could be provided by alternative methodologies, such as the Dutch model-based approach, or could be provided by European infrastructure projects.

Identifiants

pubmed: 32753239
pii: S1278-3218(20)30160-8
doi: 10.1016/j.canrad.2020.05.002
pmc: PMC7395642
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

687-690

Informations de copyright

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

D C Weber (DC)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, 144, WPTA, CH-5232 Villigen West Campus, Switzerland; University Hospital Zürich, Zürich, Switzerland; University of Bern, Bern, Switzerland. Electronic address: damien.weber@psi.ch.

J A Langendijk (JA)

Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands.

C Grau (C)

Department of Oncology and Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

J Thariat (J)

Radiation Oncology Department, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH